Member Info for stocksaint

Technology Appraisals are mandatory. Other types of guidance have become a must due to case law. It simple, when NICE issues guidance, the trusts always follow.

The trusts have to follow NICE guidance. (it wasn't always the case in the past though

It doesn't work like that Bighammer. The trusts have to start following final NICE guidance within 3 months of issue. There is no debate. You can verify this through multiple sources using Google.

The trusts always do follow NICE guidance.

(it different in USA where ultimate decision can be down to insurers/managed care providers (after FDA approval is granted))

Sebo, You might have a valid point but what NICE decides is what matters. The trusts have to follow NICE guidance. I would read the guidance that's published on Wednesday as well as any new comments and responses document that gets posted as the details are important with this.

Because I expect they'll go for central lab testing...

My best guess is share price will fall sharply after NICE update....back to 2p.

No one KNOWS what will happen tomorrow including me Slacker, but maybe you'd be better off selling out completely now before the NICE update? (In your shoes, I definitely would). It should be possible to buy in much lower again quite soon.

Seems like pump and dump crew mainly gone now, so volume is trending lower. Just LTHs and mugs left in at mo.

From the GDR press release:

"The DAP will assess the clinical and cost-effectiveness of Clopidogrel genotype testing, including any advantages of point of care testing vs central lab-based testing, in order to make recommendations on its use in the NHS."

NICE "included GDR in a diagnostic assessment programme". They intended to consider other options from the beginning. It was never all about GDR for CYP2c19:

https://www.lse.co.uk/rns/GDR/nice-includes-cyp2c19-id-kit-in-new-programme-drf7pvq16mlog4n.html

Lol, are you being serious, you didn't realise it wasn't just about Genedrive! They've considered three different options and weighed up the pros and cons of each: Lab Testing, Genedrive and the Cube.

Roger,

The NICE guidance is: "CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack"

Point being it not just about Genedrive. If they say they'll use GDR's test on just say 35,000 non-minor cases you per year, I'd expect share price to go up. But seeing as they already said lab testing was their preferred option, I don't think they will say that. This time, I would expect the guidance will be a bit more detailed than the draft with timelines and targets. If it they just say they're aiming to do all 100,000 annual tests through lab testing over such and such time frame, I would expect the share price to fall quite a bit. We'll see.

System, This will not go under. They will be back next year mounting another placing. Wouldn't like to guess at what price.

They must be out by now Slacker. The last holdings RNS was almost a month ago, and they were only holding as MM

They probably already be out. They don't need to issue more holding RNS's when they sell as they were holding as market makers and rule states that for market makers the threshold is 10% for notification.

They'll definitely be publishing on the 31st July now though

Roger,

Original delay likely as they try to work out timelines for implementation in my view as they assess lab capacity. i.e how long it will take them to get to 35,000 using lab and then 100,000. Alternative possibility, and I think much less likely, is that they've changed their mind and they're going to recommend GDR's POC as the solution for the 35,000 non-minor stroke cases.

I think the BB should be used to discuss the stock Gloria. To me silly to try and discuss posters very much. I imagine Farage uses X a lot. Neither x nor him are my cup of tea.

Deerhunter,

I've made an overall profit on GDR if you're talking about me. Not that it really matters for the purpose of the bb though. Not every single trade was a winner mind you.